Cases & Deals

  • Home
  • Practices
  • YolTech Therapeutics establishes global patent portfolios related to CRISPR-based gene editing and LNP delivery systems

Share

YolTech Therapeutics establishes global patent portfolios related to CRISPR-based gene editing and LNP delivery systems

September 2025

Client(s) YolTech Therapeutics Co., Ltd.

Jones Day is representing YolTech Therapeutics Co., Ltd., a clinical-stage in vivo gene editing company, to establish global patent portfolios related to next generation precision genetic medicines. The company's technology involves an innovative, fully integrated platform encompassing proprietary CRISPR nucleases (YolCas), base editors (YolBE), and cutting-edge lipid nanoparticle delivery systems (Yol-LNPs), which enable precise, efficient, and tissue-specific gene editing across a broad range of therapeutic areas.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.